Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer

More than 85% of colorectal cancer (CRC) patients, who are with microsatellite stability (MSS), are resistant to immune checkpoint blockade (ICB) treatment. To overcome this resistance, combination therapy with chemotherapy is the most common choice. However, many CRC patients do not benefit more fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yuhang, Sun, Haoyu, Xiao, Xinghui, Tang, Maoxing, Tian, Zhigang, Wei, Haiming, Sun, Rui, Zheng, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647086/
https://www.ncbi.nlm.nih.gov/pubmed/36389751
http://dx.doi.org/10.3389/fimmu.2022.1040256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647086/
https://www.ncbi.nlm.nih.gov/pubmed/36389751
http://dx.doi.org/10.3389/fimmu.2022.1040256

Ejemplares similares